Skip to content
10-K

Annual Report

ABVC BioPharma, Inc. ABVC

0001213900-26-023063

← back to feed
Filed
Mar 3, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 3, 2026 25.44M sh
Shares Diluted FY 2025 · Dec 31, 2025 20.11M sh
Shares Diluted FY 2025 · Dec 31, 2024 11.67M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$2.99M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$1.81M
Short Term Debt FY 2025 · Dec 31, 2025 $755.51K
Short Term Debt FY 2025 · Dec 31, 2024 $840.25K
Short Term Investments FY 2025 · Dec 31, 2025 $64.35K
Short Term Investments FY 2025 · Dec 31, 2024 $64.74K
Cash And Equivalents FY 2025 · Dec 31, 2025 $681.48K
Cash And Equivalents FY 2025 · Dec 31, 2024 $248.38K
Stockholders Equity FY 2025 · Dec 31, 2025 $11.11M
Stockholders Equity FY 2025 · Dec 31, 2024 $1.23M
Current Liabilities FY 2025 · Dec 31, 2025 $6.16M
Current Liabilities FY 2025 · Dec 31, 2024 $6.56M
Total Liabilities FY 2025 · Dec 31, 2025 $7.76M
Total Liabilities FY 2025 · Dec 31, 2024 $6.82M
Current Assets FY 2025 · Dec 31, 2025 $2.5M
Current Assets FY 2025 · Dec 31, 2024 $2.18M
Total Assets FY 2025 · Dec 31, 2025 $21.06M
Total Assets FY 2025 · Dec 31, 2024 $7.54M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.39
Eps Diluted FY 2025 · Dec 31, 2024 −$0.42
Eps Basic FY 2025 · Dec 31, 2025 −$0.39
Eps Basic FY 2025 · Dec 31, 2024 −$0.42
Sga Expense FY 2025 · Dec 31, 2025 $2.89M
Sga Expense FY 2025 · Dec 31, 2024 $2.26M
Rd Expense FY 2025 · Dec 31, 2025 $121.09K
Rd Expense FY 2025 · Dec 31, 2024 $179.27K
Net Income FY 2025 · Dec 31, 2025 −$7.91M
Net Income FY 2025 · Dec 31, 2024 −$4.9M
Operating Income FY 2025 · Dec 31, 2025 −$7.15M
Operating Income FY 2025 · Dec 31, 2024 −$4.71M
Gross Profit FY 2025 · Dec 31, 2024 $508.83K
Cost Of Revenue FY 2025 · Dec 31, 2024 $763
Revenue FY 2025 · Dec 31, 2024 $509.59K